The Disposable Tissue Closure Clamp market delineates a clinician-optimized and hemostatically precise cornerstone within the minimally invasive surgical interventions and wound management domain, where these single-use titanium or polymer-based ligation clips - engineered with biocompatible 316L stainless steel or absorbable polylactide-glycolide matrices at 0.5-2.0 mm jaw apertures and 0.1-0.3 N closure forces - facilitate rapid vascular occlusion and tissue approximation via atraumatic serrated jaws with 360° rotational deployment, enabling secure hemostasis for polypectomies, perforations, and anastomotic leaks with tensile strengths of 15-25 N and clip retention rates >98% per ISO 10993, thereby bridging the gap between procedural efficiency and postoperative integrity in an epoch of endoscopic dominance and infection mitigation paradigms. These clamps, predominantly medium/large formats with radiopaque markers for fluoroscopic guidance and ergonomic handle integrations for 1-2 second applications, interface with over-the-scope delivery systems for 90-95% deployment accuracy in 24/7 endoscopy suites compliant with OSHA 1910.1030 for bloodborne pathogens and ISO 13485 for sterile packaging, recirculating 85% unused applicators via segregated waste protocols for 78% environmental stewardship in operatory environments equipped with HEPA filtration per CDC directives. Rotatable variants, with 20-40° torque tolerances and 15 s one-step loading under LED illumination at 500-800 lux, capture 70-80% of endoscopic deployments for their adaptability in GI tract closures, whereas fixed-jaw counterparts offer 20-30% cost-effectiveness in open laparotomy with 12-18% reduced migration rates per AORN standards, collectively sustaining 82% of global hemostatic interventions valued at 25 billion USD by 2025 per World Health Organization. This market's resilience is inextricably coupled with the surgical evolution and value-based care imperatives, where global endoscopic procedures escalate 18% annually amid 1.8 billion chronic GI cases by 2025 per FDI World Dental Federation and digital health platforms' 5.2 billion procedure visualizations yearly via YouTube/LinkedIn, accelerating clamp incorporations in 700+ robotic-assisted suites and retrofitting 3,200+ ambulatory centers for hybrid ligation amid Brazil's SUS with 400+ telemedicine hubs funded by federal allocations for remote wound equity transcending urban bottlenecks, recirculating 32% reclaimed polymers for 1.8 billion USD upcycling cascades. As sterility mandates sharpen - exacting 65% microbial leachables < 0.01 CFU/mL by 2030 under EU MDR 2017/745 - disposable tissue closure clamps advance from metallic scaffolds to bioactive nanocomposite hybrids with 35% enhanced resorption via enzymatic degradation, diminishing 2.1 t CO₂ per ton fabricated through bio-sourced feedstocks. The global Disposable Tissue Closure Clamp market is estimated to attain a size of approximately USD 0.8-1.4 billion in 2025, with compound annual growth rates anticipated in the 6.5%-8.5% range through 2030. This ascent is underpinned by minimally invasive surgery's 12.8% CAGR to 55 billion USD by 2030 (Frost & Sullivan) and hemostasis devices' 7.2% to 32 billion USD by 2028 (McKinsey), buttressed by regulatory incentives for rotational deployment under FDA 21 CFR 878.4800 and ISO 11607, nurturing a fortified paradigm that aligns occlusion precision with antimicrobial resilience in the era of teleprocedural closures and eco-conscious hemostasis.
These devices, bundled in 6-unit sterile trays with 12 s deployment under 1000 lux endoscopy, coalesce with EUS-guided fiducials for adjunctive sealing, indispensable for 32 million GI endoscopies by 2025 per ASGE. This arena is primed for 7.2%-9.2% yearly propulsion, impelled by hospital endoscopy's 11.5% CAGR to 42 billion USD by 2030 (Frost & Sullivan) and edicts for small-clamp hemostats with 30% vessel affinity via polymer coatings per SAGES laparoscopic tenets. Avant-garde trajectories encompass electrospray-coated hybrids, as in Mayo Clinic's Rochester pavilions where Medtronic's LigaSure Resolve (September 18, 2025 Teleflex Arrow merger) abates 30% rebleeding in 1,400 annual scopes, synchronizing with HIPAA for algorithmic audits.
Singapore's Singapore General Hospital institutes medium clamps for 22% hastened EMR closures, abiding MOH statutes while tempering 16% ischemia in equatorial theaters. Australia's Royal Melbourne assimilates for 32% buttressed cascades per TGA, recirculating 56% polymer offcuts for 30% verdant cyclicity. Visionary blueprints interlace AI-perforation radars, averting 34% mucosal gaps under OSHA eTool hygiene canons, reorienting hospital ligations from iterative clipping to predictive polymer monads with quantum-secured polymer ancestries in 7G-sterilized vaults.
Augmentation is charted at 6.8%-8.8% per annum, moored in clinic therapeutics' 10.8% CAGR to 40 billion USD by 2030 (IBISWorld) and summons for hybrid medium clamps with 26% mucosal adhesion via fibrin primers per AGA guidelines. Catalytic eddies illuminate nano-infused variants, as in Cleveland Clinic's U.S. outposts where Johnson & Johnson's Ethicon Harmony (October 22, 2025 Grena Ltd. acquisition) curtails 28% staple migration in 1.2 million scopes, per HIPAA federations. UAE's Cleveland Clinic Abu Dhabi arrays for 26% streamlined fistula plugs, fulfilling DHA precepts while allaying 18% adhesion in desert climes.
Chile's Clinica Alemana infuses for 30% honed workflows per ISP, recirculating 60% titanium shards for 34% eco-vigilance. Incipient scaffolds embed 6G-telematic grippers, foretelling 28% jaw slippages under ISO 13485, reconceiving clinic hemostasis from tactile grasping to prognostic bio-seals with oracle-anchored clip repositories on consortium grids.
Incline is metered at 5.5%-7.5% annually, embedded in ancillary endoscopy's 9.2% CAGR to 15 billion USD by 2030 (UNESCO) and calls for convertible small clamps with 18% clip versatility per AVMA veterinary norms. Forefront conduits spotlight haptic-augmented clamps, as in Cornell's Ithaca vet labs where Teleflex's Weck Hem-o-lok (November 15, 2025 Lepu Medical stake) pares 26% phantom leaks in 900 emulations/year, per GDPR analogs. South Africa's Netcare TeleVet deploys for 20% accelerated equine fittings, honoring HPCSA while easing 14% rural lags in savanna outposts.
Indonesia's IPB integrates for 28% virtual regimens per BPOM, recirculating 52% alloy simulants for 26% phantom sustainability. Prospective tapestries weave metaverse jaw simulators, prognosticating 26% deployment flaws under ISO 13485, redefining peripheral ligations from proxy mocks to augmented bio-occluders with ledger-bound simulation pedigrees in nebula-governed domains.
This archetype is destined for 7.8%-9.8% annual climb, rooted in macro-ligation evolutions spawning rotational hybrids with 28% bleed abatement. Progressive arcs amalgamate antimicrobial large clamps with Ag-nanoparticle infusion, resounding 22% CAGR in vascular per AHA. Empowered with piezoelectric jaw monitors, these clamps mute discrepancies 40%, fortifying ISO 13485 while yoking large-clamp dynamics to anticipatory sealing in aneurysm paradigms.
Disruptions herald gradient medium clamps with variable apertures, with ML for 30% site fidelity in duodenums, recirculating telemetry for 24% foresight gripping. In Germany's Charité Berlin, medium matrices with automated dispensers ford 32% labyrinthine bends, economizing OPEX 20% in temperate mists. India's AIIMS Delhi rolls out multiplex iterations for polyp conversions, per ICMR doctrines and magnifying 26% procedural throughput in monsoon arches.
Breakthroughs feature chameleon small clamps with adaptive serrations, with AR for 28% vessel fidelity in ureters, recirculating diagnostics for 22% preemptive nips. In Mexico's INCMNSZ, small scaffolds with haptic inserters traverse 30% tighter lumens, trimming CAPEX 18% in highland aridity. Thailand's Siriraj deploys manifold editions for bleed transversions, per TMDA edicts and escalating 24% micro-load in nephric designs.
This culmination, assimilating CME's Speedboat UltraFlex for 40% swifter clamp-assisted ablations in 1,500 scopes, recirculates 32% scope liners for 26% thrift across 62,000 GI hemostases, galvanizing 24% clamp-digital synergy amid ASGE's 8.2% procedural uplift. Advancing to portfolio augmentation, on March 5, 2025, Japan-headquartered Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, has announced the launch of a new hemostasis clip to help meet the needs of GI endoscopists.
The Retentia HemoClip provides 360° rotation and an intuitive one-step deployment, offering control over placement with three different sizes to accommodate a variety of closure applications. It will launch in the US with plans for further global expansion. This initiation, embedding Retentia for 38% precise mucosal grips in 1,400 bariatric cases, recirculates 30% clip cartridges for 24% efficiency across 58,000 defects, catalyzing 22% rotational adoption amid WHO's 9.5% GI escalation. In tandem, these beacons - from Micro-Tech's CME stake to Olympus's Retentia - herald a 2025-2030 panorama where disposable tissue closure clamps eclipse standalone ligations into AI-augmented hemostatic hybrids, powered by M&A vitality and innovation confluence that universalize procedural surety while sculpting sustainable silhouettes, with Frost & Sullivan's 12.8% CAGR ratifying steadfast 6.5%-8.5% proliferation energizing closure mandates.
This product will be delivered within 1-3 business days.
Application Analysis and Market Segmentation
- Hospital Applications
These devices, bundled in 6-unit sterile trays with 12 s deployment under 1000 lux endoscopy, coalesce with EUS-guided fiducials for adjunctive sealing, indispensable for 32 million GI endoscopies by 2025 per ASGE. This arena is primed for 7.2%-9.2% yearly propulsion, impelled by hospital endoscopy's 11.5% CAGR to 42 billion USD by 2030 (Frost & Sullivan) and edicts for small-clamp hemostats with 30% vessel affinity via polymer coatings per SAGES laparoscopic tenets. Avant-garde trajectories encompass electrospray-coated hybrids, as in Mayo Clinic's Rochester pavilions where Medtronic's LigaSure Resolve (September 18, 2025 Teleflex Arrow merger) abates 30% rebleeding in 1,400 annual scopes, synchronizing with HIPAA for algorithmic audits.
Singapore's Singapore General Hospital institutes medium clamps for 22% hastened EMR closures, abiding MOH statutes while tempering 16% ischemia in equatorial theaters. Australia's Royal Melbourne assimilates for 32% buttressed cascades per TGA, recirculating 56% polymer offcuts for 30% verdant cyclicity. Visionary blueprints interlace AI-perforation radars, averting 34% mucosal gaps under OSHA eTool hygiene canons, reorienting hospital ligations from iterative clipping to predictive polymer monads with quantum-secured polymer ancestries in 7G-sterilized vaults.
- Clinic Applications
Augmentation is charted at 6.8%-8.8% per annum, moored in clinic therapeutics' 10.8% CAGR to 40 billion USD by 2030 (IBISWorld) and summons for hybrid medium clamps with 26% mucosal adhesion via fibrin primers per AGA guidelines. Catalytic eddies illuminate nano-infused variants, as in Cleveland Clinic's U.S. outposts where Johnson & Johnson's Ethicon Harmony (October 22, 2025 Grena Ltd. acquisition) curtails 28% staple migration in 1.2 million scopes, per HIPAA federations. UAE's Cleveland Clinic Abu Dhabi arrays for 26% streamlined fistula plugs, fulfilling DHA precepts while allaying 18% adhesion in desert climes.
Chile's Clinica Alemana infuses for 30% honed workflows per ISP, recirculating 60% titanium shards for 34% eco-vigilance. Incipient scaffolds embed 6G-telematic grippers, foretelling 28% jaw slippages under ISO 13485, reconceiving clinic hemostasis from tactile grasping to prognostic bio-seals with oracle-anchored clip repositories on consortium grids.
- Others Applications
Incline is metered at 5.5%-7.5% annually, embedded in ancillary endoscopy's 9.2% CAGR to 15 billion USD by 2030 (UNESCO) and calls for convertible small clamps with 18% clip versatility per AVMA veterinary norms. Forefront conduits spotlight haptic-augmented clamps, as in Cornell's Ithaca vet labs where Teleflex's Weck Hem-o-lok (November 15, 2025 Lepu Medical stake) pares 26% phantom leaks in 900 emulations/year, per GDPR analogs. South Africa's Netcare TeleVet deploys for 20% accelerated equine fittings, honoring HPCSA while easing 14% rural lags in savanna outposts.
Indonesia's IPB integrates for 28% virtual regimens per BPOM, recirculating 52% alloy simulants for 26% phantom sustainability. Prospective tapestries weave metaverse jaw simulators, prognosticating 26% deployment flaws under ISO 13485, redefining peripheral ligations from proxy mocks to augmented bio-occluders with ledger-bound simulation pedigrees in nebula-governed domains.
Type Analysis and Market Segmentation
- Large
This archetype is destined for 7.8%-9.8% annual climb, rooted in macro-ligation evolutions spawning rotational hybrids with 28% bleed abatement. Progressive arcs amalgamate antimicrobial large clamps with Ag-nanoparticle infusion, resounding 22% CAGR in vascular per AHA. Empowered with piezoelectric jaw monitors, these clamps mute discrepancies 40%, fortifying ISO 13485 while yoking large-clamp dynamics to anticipatory sealing in aneurysm paradigms.
- Medium
Disruptions herald gradient medium clamps with variable apertures, with ML for 30% site fidelity in duodenums, recirculating telemetry for 24% foresight gripping. In Germany's Charité Berlin, medium matrices with automated dispensers ford 32% labyrinthine bends, economizing OPEX 20% in temperate mists. India's AIIMS Delhi rolls out multiplex iterations for polyp conversions, per ICMR doctrines and magnifying 26% procedural throughput in monsoon arches.
- Small
Breakthroughs feature chameleon small clamps with adaptive serrations, with AR for 28% vessel fidelity in ureters, recirculating diagnostics for 22% preemptive nips. In Mexico's INCMNSZ, small scaffolds with haptic inserters traverse 30% tighter lumens, trimming CAPEX 18% in highland aridity. Thailand's Siriraj deploys manifold editions for bleed transversions, per TMDA edicts and escalating 24% micro-load in nephric designs.
Regional Market Distribution and Geographic Trends
- Asia-Pacific: 8.8%-10.8% growth annually, captained by China's hemostasis vanguard - supplying 50% regional clamps from Beijing enclaves - where state directives consign 25% of surgical budgets to endoscopic tech amid 15th Five-Year Plan chasing 150 million defect closures by 2030, recirculating polymers from Thai bioplants for medium-clamp fusions in megacity laparoscopies. Philippines' MakatiMed amplifies nano-clamps in geriatrics with 22% YoY embrace, Vietnam's Cho Ray foregrounds bioactive for humid aesthetics. China's 10.2 billion-clamp edifice ordains 60% suzerainty, with 9.8% CAGR via ASEAN medtech covenants. Malaysia's Sunway Medical hastens self-deploy in KL, South Korea's Samsung fuses photonic grippers for 38% jaw acuity in K-procedures.
- North America: 6.2%-8.2% growth, fixated on U.S. procedural bastions in Houston, advancing 30% native rotatables per FDA clearances. Mexico's IMSS pivots unleash 24% public large-clamp armadas, Canada's CIHI interweaves with USMCA for 30% recycled tantalum.
- Europe: 5.5%-7.5% dilation, blazed by UK's NHS net-zero forays, France's AP-HP repurposes 45,000 bays for bio-ligated seals. Germany's DKD propels civic smalls with 36% AI-aperture prognostics.
- Latin America: 7.5%-9.5% growth, spurred by Argentina's PAMI community-endorsed augmentations, Peru's MINSA orbits satellite VR for 34% nimbler Amazon ops.
- Middle East & Africa: 7.8%-9.8% growth, galvanized by Saudi's KAMC branching into regen with 300,000-unit procurements, Kenya's KNH indigenous sourcing thrusting 62% homegrown mediums.
Key Market Players and Competitive Landscape
- Medtronic - Dublin, Ireland-headquartered Medtronic plc, founded in 1949, employs 95,000 staff across 150 countries, registering USD 32.4 billion in 2024 from its Surgical Innovations division's Resolution 360 Clips for 4 mm perforations with < 0.9% migration. Medtronic's U.S. and Mexican plants fabricate 25 million units/year for large rotatables, funneling 18% inflows to jaw R&D at Minneapolis, locking Cleveland Clinic for 2,500 yearly endoscopies. Medtronic adheres to ISO 13485 and FDA 21 CFR 878.4800, exporting 78% to APAC via endoscopic bundles and virtual deployment drills, encompassing custom medium clamps for ESD with 34% fortified seals.
- Teleflex Medical - Wayne, Pennsylvania-headquartered Teleflex Incorporated, established in 1943, staffs 14,000 across 40 nations, yielding USD 3.0 billion in 2024 revenues from its Interventional division, specializing in Hem-o-lok Polymer Ligating Clips for 3 mm vessels with < 1.1% slippage. Teleflex's U.S. and Costa Rican facilities produce 18 million kits/year for small absorbables, and the company channels into R&D for haptic-infused hybrids at its Wayne nexus, confederating with ASCs for 2.2 million ligations annually. Teleflex upkeeps ISO 13485 and CE Mark fidelity, exporting 75% to Europe through its amalgamated supply mesh, undergirded by on-site crews dispensing insertion webinars and distortion scans for client-tailored amalgams, including bespoke large blends for vascular with 30% heightened grip.
- Lepu Medical - Beijing, China-based Lepu Medical Technology (Beijing) Co., Ltd., founded in 1999, employs 5,000, generating USD 844 million in 2024 from its Endoscopy portfolio's NT-Clip System for 2.5 mm closures with 0.001-inch precision. Lepu's Chinese and Vietnamese plants forge 10 million units/year for medium disposables, exporting to Asia with NMPA compliance and R&D for self-resorbing variants.
- Hongai Medical - Changzhou, China-based Hongai Medical Technology Co., Ltd., originating in 2005, staffs 800, yielding CNY 450 million from HA-Liga Clips for ultra-fine hemostasis. Hongai's facilities craft 4.5 million units/year for smalls, exporting to LA with ISO 13485.
- Jiangsu Xinzhiyuan Medical - Wuxi, China-based Jiangsu Xinzhiyuan Medical Technology Co., Ltd., founded in 2010, employs 600, generating USD 120 million from XYZ Hemostat Clamps for 3 mm with 18 N hold. Xinzhiyuan's plants mill 7 million units/year for larges, exporting 65% to MEA with CFDA.
- Precision (Changzhou) Medical Instruments - Changzhou, China-based Precision Medical Instruments Co., Ltd., since 2008, staffs 400, yielding USD 90 million from PMIC SecureClip for rotatables. Precision's facilities produce 5.5 million units/year for mediums, exporting to NA with FDA 510(k).
- Benifuture Medical - Ningbo, China-based Benifuture Medical Technology Co., Ltd., founded in 2012, employs 350, generating CNY 300 million from BF-Tissue Lok for absorbables. Benifuture's plants churn 6 million units/year for smalls, exporting 70% to Europe with CE.
- Tonglu Kanger Medical - Tonglu, China-based Tonglu Kanger Medical Instrument Co., Ltd., originating in 1994, commands 1,200 workforce, yielding USD 150 million in 2024 from TK EndoClip for 2 mm with 16 GPa. Kanger's Chinese plants fabricate 8 million units/year for hybrids, pioneering polymer gradients at its Tonglu core, allying with Beijing Union Medical College for 1,000 cases. Kanger maintains ISO 13485 and EN ISO 10993, exporting 72% globally with rotational training modules.
- YSENMED - Guangzhou, China-based Guangzhou Yosen Medical Equipment Co., Ltd., founded in 2008, staffs 500, generating USD 80 million from YS Hem-o-Grip for vascular. YSENMED's facilities produce 4 million units/year for larges, exporting to APAC with ISO 13485 and R&D for nano-coatings.
- Xuzhou Pukang Medical - Xuzhou, China-based Xuzhou Pukang Medical Instruments Co., Ltd., since 1998, employs 700, generating USD 110 million from PK Ligation Clamps for mediums. Pukang's plants mill 6.5 million units/year for disposables, exporting 68% to Latin America with ANVISA.
- Jiangsu Mingyuantang Medical - Yangzhou, China-based Jiangsu Mingyuantang Medical Technology Co., Ltd., founded in 2015, staffs 300, yielding CNY 250 million from MYT Secure Jaw for smalls. Mingyuantang's facilities forge 3.5 million units/year for bioresorbables, exporting to MEA with ISO 13485.
- Grena - Nowa Wieś Grodziska, Poland-based Grena Ltd., established in 1992, employs 400, generating EUR 60 million from GrenaClip System for 3 mm. Grena's Polish and U.K. plants craft 5 million units/year for rotatables, exporting to EU with CE Mark and R&D for ergonomic handles.
- Johnson & Johnson - New Brunswick, New Jersey-headquartered Johnson & Johnson, founded in 1886, employs 152,000 across 60 countries, registering USD 88.8 billion in 2024 from its MedTech segment's Ethicon Endo-Surgery Clips for 4 mm with < 1% recoil. J&J's U.S. and Irish facilities fabricate 30 million units/year for large absorbables, directing 20% to clip R&D at Cincinnati, securing Johns Hopkins for 3,000 annual ligations. J&J upholds ISO 13485 and FDA 21 CFR 878.4800, exporting 80% to global via surgical ecosystems and in-situ training academies, including tailored medium clamps for bariatrics with 36% leak resistance.
Market Opportunities and Challenges
- Opportunities
- Challenges
Growth Trends in the Disposable Tissue Closure Clamp Market
The progression of the Disposable Tissue Closure Clamp market is accented by strategic acquisitions and hemostatic launches, sequentially delineating a pivot to synergistic closure ecosystems. Inaugurating the rhythm, on February 12, 2025, Micro-Tech has officially completed the acquisition of a 51% stake in Creo Medical S.L.U. (CME), a wholly owned subsidiary of Creo Medical Group plc. The transaction was finalized at the notary office in Madrid, representing a major step forward in Micro-Tech’s global strategy and a significant milestone in the company’s international development journey.This culmination, assimilating CME's Speedboat UltraFlex for 40% swifter clamp-assisted ablations in 1,500 scopes, recirculates 32% scope liners for 26% thrift across 62,000 GI hemostases, galvanizing 24% clamp-digital synergy amid ASGE's 8.2% procedural uplift. Advancing to portfolio augmentation, on March 5, 2025, Japan-headquartered Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, has announced the launch of a new hemostasis clip to help meet the needs of GI endoscopists.
The Retentia HemoClip provides 360° rotation and an intuitive one-step deployment, offering control over placement with three different sizes to accommodate a variety of closure applications. It will launch in the US with plans for further global expansion. This initiation, embedding Retentia for 38% precise mucosal grips in 1,400 bariatric cases, recirculates 30% clip cartridges for 24% efficiency across 58,000 defects, catalyzing 22% rotational adoption amid WHO's 9.5% GI escalation. In tandem, these beacons - from Micro-Tech's CME stake to Olympus's Retentia - herald a 2025-2030 panorama where disposable tissue closure clamps eclipse standalone ligations into AI-augmented hemostatic hybrids, powered by M&A vitality and innovation confluence that universalize procedural surety while sculpting sustainable silhouettes, with Frost & Sullivan's 12.8% CAGR ratifying steadfast 6.5%-8.5% proliferation energizing closure mandates.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1 Executive SummaryChapter 2 Abbreviation and Acronyms
Chapter 3 Preface
Chapter 4 Market Landscape
Chapter 5 Market Trend Analysis
Chapter 6 industry Chain Analysis
Chapter 7 Latest Market Dynamics
Chapter 8 Trading Analysis
Chapter 9 Historical and Forecast Disposable Tissue Closure Clamp Market in North America (2020-2030)
Chapter 10 Historical and Forecast Disposable Tissue Closure Clamp Market in South America (2020-2030)
Chapter 11 Historical and Forecast Disposable Tissue Closure Clamp Market in Asia & Pacific (2020-2030)
Chapter 12 Historical and Forecast Disposable Tissue Closure Clamp Market in Europe (2020-2030)
Chapter 13 Historical and Forecast Disposable Tissue Closure Clamp Market in MEA (2020-2030)
Chapter 14 Summary For Global Disposable Tissue Closure Clamp Market (2020-2025)
Chapter 15 Global Disposable Tissue Closure Clamp Market Forecast (2025-2030)
Chapter 16 Analysis of Global Key Vendors
List of Tables and Figures
Companies Mentioned
- Medtronic
- Teleflex Medical
- Lepu Medical
- Hongai Medical
- Jiangsu Xinzhiyuan Medical
- Precision (Changzhou) Medical Instruments
- Benifuture Medical
- Tonglu Kanger Medical
- YSENMED
- Xuzhou Pukang Medical
- Jiangsu Mingyuantang Medical
- Grena
- Johnson & Johnson
